JPMorgan Chase & Co. Grows Stock Holdings in Merit Medical Systems, Inc. $MMSI

JPMorgan Chase & Co. increased its position in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 7.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 917,122 shares of the medical instruments supplier’s stock after buying an additional 64,920 shares during the period. JPMorgan Chase & Co.’s holdings in Merit Medical Systems were worth $76,332,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Salomon & Ludwin LLC bought a new position in shares of Merit Medical Systems in the third quarter worth about $37,000. EverSource Wealth Advisors LLC raised its stake in Merit Medical Systems by 745.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 922 shares of the medical instruments supplier’s stock valued at $86,000 after purchasing an additional 813 shares during the period. First Horizon Corp purchased a new position in Merit Medical Systems in the 3rd quarter worth approximately $78,000. Palouse Capital Management Inc. boosted its stake in Merit Medical Systems by 27.5% in the 3rd quarter. Palouse Capital Management Inc. now owns 1,076 shares of the medical instruments supplier’s stock worth $90,000 after purchasing an additional 232 shares during the period. Finally, Smartleaf Asset Management LLC grew its holdings in Merit Medical Systems by 28.7% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,663 shares of the medical instruments supplier’s stock valued at $134,000 after buying an additional 371 shares in the last quarter. 99.66% of the stock is owned by institutional investors.

Key Stories Impacting Merit Medical Systems

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Q4 beat — Merit reported $1.04 EPS versus the $0.96 consensus and revenue of $393.94M vs. $390.77M, with revenue up ~10.9% year-over-year; these results directly support the share-price uptick. Read More.
• Positive Sentiment: Raised FY2026 guidance — Management set FY26 EPS guidance of $4.010–4.150 versus the street at ~3.73, which boosts forward earnings expectations and valuation support. Read More.
• Neutral Sentiment: Key operating metrics — Return on equity (~14.3%) and net margin (~8.0%) were disclosed; these confirm healthy profitability but also imply a premium multiple (P/E ~42), so upside depends on durable margin expansion. Read More.
• Neutral Sentiment: Investor materials & call available — Management hosted a conference call and posted slides/transcript (useful for hearing color on procedure demand, margins, and buyback/capex plans). Read More.
• Neutral Sentiment: Media coverage — Multiple outlets summarized the beat and guidance; these stories help circulate the positive surprise but add no new company-specific data. Read More.

Merit Medical Systems Stock Up 1.0%

NASDAQ MMSI opened at $82.43 on Wednesday. The company has a quick ratio of 2.86, a current ratio of 4.28 and a debt-to-equity ratio of 0.48. The company has a fifty day moving average of $84.08 and a two-hundred day moving average of $84.98. Merit Medical Systems, Inc. has a 52 week low of $77.62 and a 52 week high of $107.27. The firm has a market capitalization of $4.89 billion, a price-to-earnings ratio of 42.27, a PEG ratio of 2.22 and a beta of 0.61.

Analyst Upgrades and Downgrades

Several research firms have recently commented on MMSI. Needham & Company LLC reissued a “buy” rating and issued a $108.00 target price on shares of Merit Medical Systems in a report on Friday, January 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of Merit Medical Systems in a research note on Monday, December 29th. Robert W. Baird set a $108.00 price objective on Merit Medical Systems in a research report on Tuesday, December 16th. BTIG Research initiated coverage on Merit Medical Systems in a research report on Friday, February 6th. They issued a “buy” rating and a $107.00 target price on the stock. Finally, Zacks Research lowered Merit Medical Systems from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 18th. Nine analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $105.67.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.